Proven Solutions for Clinical Research Applications - Agilent clinical research solutions
Brochures and specifications | 2018 | Agilent TechnologiesInstrumentation
Clinical research increasingly relies on high-throughput, robust, and sensitive analytical methods to quantify small molecules, peptides, biomarkers, and trace elements in complex biological matrices. Achieving consistent accuracy and reproducibility supports drug development, therapeutic monitoring, and biomarker discovery, ultimately advancing personalized medicine.
This summary reviews Agilent’s integrated solutions designed for routine and research-level clinical workflows. It highlights instrument combinations, analytical methods, and performance metrics that demonstrate how laboratories can optimize space, throughput, and ease of use for quantitative analysis.
Agilent provides a comprehensive suite of platforms:
Agilent solutions demonstrate:
Laboratories can leverage these methods for:
Emerging directions include deeper integration of automation and robotics for sample preparation, machine-learning–driven data analysis, expanded retrospective screening capabilities, miniaturization of LC/MS platforms, and personalized multi-omics studies. Advances in triple quadrupole and Q-TOF technologies will further lower detection limits and broaden clinical research applications.
Agilent’s portfolio of clinical research solutions addresses the demanding needs of modern laboratories by combining sensitivity, throughput, and automation. These integrated platforms facilitate reliable quantitation across small molecules, peptides, and elements, supporting translational research and clinical assays with high robustness and reproducibility.
GC/MSD, GC/MS/MS, GC/HRMS, Sample Preparation, GC/TOF, Consumables, HPLC, LC/TOF, LC/HRMS, LC/MS, LC/MS/MS, LC columns, LC/QQQ, ICP/MS, ICP/MS/MS
IndustriesClinical Research
ManufacturerAgilent Technologies
Summary
Significance of the Topic
Clinical research increasingly relies on high-throughput, robust, and sensitive analytical methods to quantify small molecules, peptides, biomarkers, and trace elements in complex biological matrices. Achieving consistent accuracy and reproducibility supports drug development, therapeutic monitoring, and biomarker discovery, ultimately advancing personalized medicine.
Objectives and Study Overview
This summary reviews Agilent’s integrated solutions designed for routine and research-level clinical workflows. It highlights instrument combinations, analytical methods, and performance metrics that demonstrate how laboratories can optimize space, throughput, and ease of use for quantitative analysis.
Methodology and Instrumentation
Agilent provides a comprehensive suite of platforms:
- High-throughput LC/MS/MS: 1260 Infinity II Prime LC coupled with Ultivo or 6490/6470/6495B triple quadrupole systems for targeted quantitation of drugs, hormones, and metabolites.
- Peptide quantitation: Jet Stream proteomics solution on 1290 Infinity II LC for analytical-flow peptide assays, supported by AssayMAP Bravo automation and Captiva online cleanup.
- Omics discovery workflows: 6550 iFunnel Q-TOF LC/MS, 6230B TOF, 7200B GC/Q-TOF, and Mass Profiler Professional software for proteomics and metabolomics profiling.
- Elemental analysis: 7500cx, 7800, 7900, and 8900 triple quadrupole ICP-MS with graphite furnace and collision/reaction cells for trace metals and nonmetals in fluids.
- Complementary techniques: Capillary electrophoresis–TOF, GC/MS, and automated sample preparation modules for multi-omics integration.
Main Results and Discussion
Agilent solutions demonstrate:
- Sub-ppb detection limits for drugs, steroids, and neurotransmitters in serum, urine, and whole blood.
- Accurate quantitation of peptides and phosphopeptides at analytical flow rates with retention time reproducibility enabling automated data extraction.
- Automated cleanup strategies (Captiva EMR, online extraction) to streamline sample throughput and reduce matrix effects.
- Trace element profiling (Pb, Se, Zn, Cu) with improved sensitivity and matrix control via triple quadrupole ICP-MS.
- Retrospective data mining using LC/Q-TOF for broad-spectrum screening alongside targeted assays.
Benefits and Practical Applications
Laboratories can leverage these methods for:
- Routine QA/QC quantitation of therapeutic drugs and endogenous compounds.
- High-throughput biomarker validation in clinical trials.
- Integrated multi-omics research, combining genomics, transcriptomics, proteomics, metabolomics, and elemental analysis.
- Automated workflows that minimize hands-on time and maximize reproducibility.
- Comprehensive service and support from Agilent CrossLab, ensuring instrument uptime and application optimization.
Future Trends and Possibilities
Emerging directions include deeper integration of automation and robotics for sample preparation, machine-learning–driven data analysis, expanded retrospective screening capabilities, miniaturization of LC/MS platforms, and personalized multi-omics studies. Advances in triple quadrupole and Q-TOF technologies will further lower detection limits and broaden clinical research applications.
Conclusion
Agilent’s portfolio of clinical research solutions addresses the demanding needs of modern laboratories by combining sensitivity, throughput, and automation. These integrated platforms facilitate reliable quantitation across small molecules, peptides, and elements, supporting translational research and clinical assays with high robustness and reproducibility.
References
- Agilent application note 5991-8845EN: Detection of Synthetic Fentanyl Analogues
- Agilent application note 5991-8214EN: Simultaneous Quantitation of Antiepileptic Drugs
- Agilent application note 5991-7956EN: Vitamin D Metabolite Analysis
- Agilent application note 5991-2900EN: StreamSelect LC/MS Productivity
- Agilent application note 5991-7298EN: Extended Mass Range Triple Quadrupole
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Agilent LC Triple Quadrupole Clinical Research Compendium
2021|Agilent Technologies|Guides
Agilent LC Triple Quadrupole Clinical Research Compendium Application Compendium Table of contents Contents Introduction 4 Routine analysis 5 Hormones 5 Progesterone Metabolism in Serum 5 Analytical Determination of Testosterone in Human Serum Using an Agilent Ultivo Triple Quadrupole LC/MS 7…
Key words
atturos, atturoscounts, countsplasma, plasmaagilent, agilentstreamselect, streamselectserum, serummel, meltriple, triplequadrupole, quadrupolecaptiva, captivathc, thcusing, usingtestosterone, testosteronemethod, methodresponses
Analysis of Hydroxychloroquine and Metabolites in Human Serum and Plasma Using the Agilent Captiva EMR—Lipid by LC-QQQ
2021|Agilent Technologies|Applications
Application Note Clinical Research Analysis of Hydroxychloroquine and Metabolites in Human Serum and Plasma Using the Agilent Captiva EMR—Lipid by LC-QQQ Authors Anne-Laure Larroque Center for Translational Biology (CTB) Drug Discovery Platform, Research Institute of the McGill University Health Center…
Key words
hcq, hcqauc, auchuman, humanhydroxychloroquine, hydroxychloroquinedcq, dcqdhcq, dhcqbdcq, bdcqserum, serumanalyte, analytematrix, matrixplasma, plasmaspiking, spikingblood, bloodaccuracy, accuracycaptiva
Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR—Lipid Cleanup
2018|Agilent Technologies|Applications
Application Note Forensic Testing Quantitative Determination of Drugs of Abuse in Human Plasma and Serum by LC/MS/MS Using Agilent Captiva EMR—Lipid Cleanup Author Limian Zhao Agilent Technologies, Inc. Abstract Agilent Captiva Enhanced Matrix Removal—Lipid (EMR—Lipid) is the second generation of…
Key words
captiva, captivaemr, emrlipid, lipidblood, blooddoa, doahuman, humanserum, serumplasma, plasmamatrix, matrixppt, pptabuse, abuseloq, loqmixing, mixingdrugs, drugswere
Sensitive Analysis for Per- and Polyfluoroalkyl Substances (PFAS) in Whole Blood
2024|Agilent Technologies|Applications
Application Note Clinical Research Sensitive Analysis for Per- and Polyfluoroalkyl Substances (PFAS) in Whole Blood Authors Emily Parry, Jennifer Hitchcock, and Limian Zhao Agilent Technologies, Inc. Abstract This application note demonstrates a sensitive workflow for the extraction and analysis of…
Key words
ppt, pptemr, emrcaptiva, captivalipid, lipidwhole, wholepfas, pfasblood, bloodpolyfluoroalkyl, polyfluoroalkylcapitva, capitvasolvent, solventmefose, mefosesubstances, substancesprecipitation, precipitationonly, onlyprotein